$TCBI

TEXAS CAPITAL BANCSHARES INC/TX (TCBI): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

TEXAS CAPITAL BANCSHARES INC/TX (TCBI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 16, 2026, Texas Capital Bancshares, Inc. (the “Company”) announced that the Company and David Oman mutually d

Original reporting
Published Sep 16, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 8:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$TCBI
Neutral
high confidence
Mentioned
$TCBI
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$TCBINeutralLow
01

Why it matters

The change is operational with no immediate financial ramifications; investors may monitor for any subsequent risk policy updates.

02

Market read

Low relevance; routine executive transition with minimal trading impact.

03

What to watch

Potential hidden compensation adjustments or future strategic shifts not disclosed.

Relevance 6/10Novelty 4/10Timing: effective September 16, 2026

Background

Texas Capital Bancshares Inc. filed an 8‑K announcing the CRO's departure and interim coverage.

Company-level read

Ticker impact

$TCBINeutralHigh confidence
Context

SEC 8‑K reports the departure of Chief Risk Officer David Oman and interim coverage by David Youngberg.

Expected impact

minimal short‑term movement expected

Evidence & confidence

The filing is a routine executive transition with no disclosed compensation changes or strategic shift.

Market effects

Limited impact on regional banking sector; similar officer changes are common.

No discernible effect on broader Texas or US banking markets.

None

Counterpoint

If the CRO departure signals deeper risk issues, the stock could face pressure.

Key entities

  • David Oman

    Departing Chief Risk Officer

  • David Youngberg

    Chief Credit Officer assuming CRO duties

Related articles

$TCBIMedAI 8/10

Third Coast to buy Oklahoma bank for $240M

Third Coast Bancshares (TCBK) will acquire Great Plains Bancshares and its subsidiary, Great Plains National Bank, for $239.6M in stock. The deal, expected to close in Q1 2027, will create a combined entity with $9B in assets and 43 branches. Great Plains reported $1.9B in assets, $1.7B in loans, and $1.7B in deposits as of June.

$TCBIMed

Texas Capital to Bring Corporate Listing Home to the Texas Stock Exchange

TEXAS CAPITAL BANCSHARES INC/TX (TCBI) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 MEDIA CONTACT Julia Monter julia.monter@texascapital.com INVESTOR CONTACT Jocelyn Kukulka investor.relations@texascapital.com Texas Capital to Bring Corporate Listing Home to the Texas Stock Exchange Full-service, Texas-founded and headquartered financial services fi

$TCBIMed

TEXAS CAPITAL BANCSHARES, INC. ANNOUNCES SECOND QUARTER 2026 RESULTS

TEXAS CAPITAL BANCSHARES INC/TX (TCBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a07222026exhibit991.htm EX-99.1 EARNINGS RELEASE Document Exhibit 99.1 INVESTOR CONTACT Jocelyn Kukulka, 469.399.8544 jocelyn.kukulka@texascapital.com Dallas, TX - July 22, 2026 TEXAS CAPITAL BANCSHARES, INC. ANNOUNCES SECOND QUARTER 2026 RESULTS Second quarter 2026 net

$XFORMed

X4 Strengthens Cash Position Ahead Of Key Phase 3 Milestones

X4 Pharmaceuticals (XFOR) secured a $150M senior secured debt facility from K2 HealthVentures, replacing its previous loan. The initial $80M tranche was used to repay existing debt, with an additional $70M available. The company aims to advance mavorixafor (XOLREMDI) for chronic neutropenia, with Phase 3 trial results expected in 2028. XFOR stock closed at $2.81, up 1.44%.